Macrogenics (MGNX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MGNX Macrogenics

Watchlist

4.120
+0.140+3.52%

Close Oct 16 16:00 ET

4.240
+0.120+2.91%

Post 19:59 ET

258.42MMarket Cap-1881P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Yahoo FinanceSep 26 08:20 ET
Express News | MacroGenics Shares Down 7.4% as Data Shows Worsening Safety Profile for Co's Prostate Cancer Drug
ReutersSep 16 13:20 ET
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
Moomoo NewsSep 16 08:31 ET · Ratings
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Moomoo NewsSep 16 08:31 ET · Ratings
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating
Moomoo NewsSep 16 08:31 ET · Ratings
MacroGenics (MGNX) Receives a Hold From TD Cowen
TipRanksSep 16 07:46 ET · Ratings

Comments

Stock_Drift

Sep 15 04:34

They want LESS to be better. No Moomoo research doctors are allowed to comment without a minimum of 2000 peer reviewed research hours. And that’s a low # if you know.

$Macrogenics (MGNX.US)$

SpeedUp21

Sep 15 02:42

$Macrogenics (MGNX.US)$ get up and let's go..

Jaguar8

Sep 15 02:39

WEEKEND NEWS

$Macrogenics (MGNX.US)$
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...

Jaguar8

Sep 8 18:11

NEWS

$Macrogenics (MGNX.US)$
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...